ROCKVILLE, Md., May 17, 2016 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused
on developing therapeutics to protect the gut microbiome, announced
today that the Company is scheduled to host a conference call on
Monday, May 23, 2016, at 8:30 a.m. (EDT) to review IBS-C patient data from
the first and second Phase 2 clinical trials for SYN-010. Synthetic
Biologics previously reported positive topline data from both Phase
2 clinical trials, including a reduction in breath methane levels,
abdominal pain and bloating, and an increase in the frequency of
complete spontaneous bowel movements.
During the call, Dr. Mark
Pimentel, Director of the GI Motility Program and Laboratory
at Cedars-Sinai, intends to recap the SYN-010 results to be
included in the poster presentation at Digestive Disease Week®
(DDW® 2016) on Sunday, May 22, 2016
in San Diego. The dial-in
information for the call is as follows:
U.S. toll free: 1-888-347-5280
International: +1 412-902-4280.
Participants are asked to dial in 15 minutes before the start of
the call to register. The call and associated slide presentation
will be webcast over the Internet at
https://www.webcaster4.com/Webcast/Page/1096/14387. An archive of
the call will be available for approximately six months at the same
URL https://www.webcaster4.com/Webcast/Page/1096/14387 beginning
approximately one hour after the call's conclusion.
About SYN-010
SYN-010 is a proprietary, modified-release formulation of
lovastatin lactone that is intended to reduce methane production by
certain microorganisms (M. smithii) in the gut while
minimizing disruption to the microbiome to treat an underlying
cause of IBS-C. SYN-010 is intended
to act primarily in the intestinal lumen while avoiding systemic
absorption, thereby targeting a major cause of IBS-C, not just the
symptoms. To access the SYN-010 mechanism of action video on
Synthetic Biologics' website, please click here.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage
company developing therapeutics to protect the gut microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development are: (1) SYN-010 which is intended to reduce
the impact of methane producing organisms in the gut microbiome to
treat an underlying cause of irritable bowel syndrome with
constipation (IBS-C), and (2) SYN-004 which is designed to protect
the gut microbiome from the effects of certain commonly used
intravenous (IV) beta-lactam antibiotics for the prevention of
C. difficile infection and antibiotic-associated diarrhea
(AAD). In collaboration with Intrexon Corporation, the Company is
also developing preclinical stage monoclonal antibody therapies for
the prevention and treatment of pertussis and novel discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
some cases forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions, and include statements
regarding the potential benefits of SYN-004 and SYN-010. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this press release and are
subject to a number of risks and uncertainties, many of which are
difficult to predict that could cause actual results to differ
materially from current expectations and assumptions from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
current expectations include, among others, Synthetic
Biologics' product candidates demonstrating safety and
effectiveness, as well as results that are consistent with prior
results, Synthetic Biologics' ability to initiate clinical trials
and if initiated, to complete them on time and achieve desired
results and benefits, Synthetic Biologics' clinical trials
continuing enrollment as expected, Synthetic Biologics' ability to
obtain regulatory approvals for commercialization of product
candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to Synthetic Biologics' ability to
promote or commercialize its product candidates for specific
indications, acceptance of its product candidates in the
marketplace and the successful development, marketing or sale of
Synthetic Biologics' products, Synthetic Biologics' ability to
maintain its license agreements, the continued maintenance and
growth of Synthetic Biologics' patent estate, Synthetic Biologics
becoming and remaining profitable, Synthetic Biologics' ability to
establish and maintain collaborations, Synthetic Biologics' ability
to obtain or maintain the capital or grants necessary to fund its
research and development activities, a loss of any of Synthetic
Biologics' key scientists or management personnel, and other
factors described in Synthetic Biologics' Annual Report on Form
10-K for the year ended December 31,
2015 and its other filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. The information
in this release is provided only as of the date of this release,
and Synthetic Biologics undertakes no obligation to update any
forward-looking statements contained in this release on account of
new information, future events, or otherwise, except as required by
law.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-host-post-ddw-2016-conference-call-to-recap-syn-010-phase-2-clinical-trial-results-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c-300269616.html
SOURCE Synthetic Biologics, Inc.